Sophie Humbert

Sophie Humbert brings to LimFlow over 15 years of experience in the medtech industry, with a strong track record of bringing innovation from ideation to market. As a driven and structured entrepreneur, she has been CEO and COO of a number of medtech start-ups in the cardiovascular, endovenous and oncology arenas.

Prior to joining LimFlow, Sophie was the COO of ART, an innovative and multicultural company designing bioresorbable stents for cardiovascular applications. She helped the company earn CE mark for their first generation product and also develop the second generation drug coated bioresorbable stent. As CEO of CermaVein, Sophie successfully led the company from an early development stage, through CE marking, and to commercialization in several markets. Earlier in her career, Sophie held R&D leadership positions within Cerma and Bracco Diagnostics. Sophie holds a PhD in Pharmaceutical Sciences from the University of Geneva, a Master’s degree in Management from EM Lyon and a Pharma doctorate from the University Claude Bernard in Lyon.